Insights into how to better understand and treat COVID-19 are desperately needed. Given the importance and urgency in obtaining these insights, it is critical for the scientific community to come together around this shared purpose.

A new Finnish study demonstrated the benefits of large-scale genomic information in estimating the risk of onset for cardiac diseases, diabetes and common cancers. The findings, based on the FinnGen research dataset encompassing more than 135,000 Finns, show that new tools based on genomic data are helpful in identifying high-risk individuals not identified by the current system.

FinnGen, a large-scale academic – industry, genome research collaboration in Finland now includes eleven industry partners with the addition of the Janssen Pharmaceutical Companies of Johnson & Johnson and Maze Therapeutics.

We are excited to announce that the FinnGen data freeze 2 results and summary statistics are now publicly available!

What are the benefits of FinnGen and Finland for our industry partners? This autumn we took the opportunity to interview some representatives of our pharmaceutical partners who wanted to share their experiences of FinnGen.

Results based on the FinnGen data are presented in several talks and posters during the 69th Annual Meeting of the American Society of Human Genetics (ASHG) in Houston, October 15-19. Come and meet our researchers!

The next FinnGen Face-to-Face meeting will be organized 11 - 12 September in Helsinki. 

With this new animation we hope to be able to explain all the essential characteristics of the FinnGen study in a way that is both entertaining and enlightening.

HELSINKI, Finland, January 22, 2019

GSK and Sanofi have joined the FinnGen study, a large public private partnership aiming to collect and analyse genome and health data from 500 000 Finns and thereby generate novel medically and therapeutically relevant insights.

Several FinnGen researchers are participating in the ASHG 2018 meeting.